Ozempic vs. Wegovy: label differences and cost checks

A shared ingredient does not make the brands interchangeable

Ozempic and Wegovy both contain semaglutide, yet they are distinct products with different FDA-labeled indications and pen presentations. Begin the comparison there. The authorized cost source provides dated Ozempic terms checked on 2026-07-23 but no current Wegovy price. The commercial comparison therefore remains uneven until current product-specific evidence supplies the missing field.

Use the brand name whenever summarizing a label or commercial term. A note that says semaglutide price can accidentally combine an Ozempic pharmacy quote with a Wegovy plan response. Bind every fact to its brand, source ID, and check date. The cited evidence does not compare outcomes, administration schedules, personal factors, or product rank.

The cited Ozempic label states that Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It also lists reduction of major adverse cardiovascular events, cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, in adults with type 2 diabetes mellitus and established cardiovascular disease. The adult, type 2 diabetes, and established-disease qualifiers belong with the cardiovascular statement.

The third indication is reduction of the risk of sustained estimated-glomerular-filtration-rate decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. The cited Ozempic label doesn't list chronic weight management. Preserve that boundary when describing FDA status. Do not replace the three exact uses with a broad diabetes-or-weight phrase, and don't borrow a Wegovy indication merely because both labels name semaglutide.

What the Wegovy label says

The cited Wegovy label states that Wegovy is indicated with a reduced-calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events, cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, in adults with established cardiovascular disease and either obesity or overweight. Unlike the Ozempic cardiovascular statement, this population wording is not built around type 2 diabetes. Keep the brand and every population qualifier attached.

The same label includes reducing excess body weight and maintaining weight reduction long term in adults and pediatric patients age 12 or older with obesity, and in adults with overweight plus at least one weight-related comorbid condition. It also includes treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis, formerly called NASH, with moderate to advanced liver fibrosis consistent with stages F2 to F3 in adults. These are separate FDA statements, not performance comparisons.

The Wegovy prescribing information says the noncirrhotic MASH indication was approved under accelerated approval based on improvement of MASH and fibrosis. It further states that continued approval may depend on verification and description of clinical benefit in a confirmatory trial. That regulatory qualifier is part of the exact status record. Omitting it would make the indication summary less precise than the cited label, even though the cited evidence does not examine study results.

Record the label revision beside the MASH statement. The checklist entry needs the brand, indication wording, adult population, noncirrhotic status, fibrosis range, accelerated-approval note, source, and check date. This is evidence maintenance, not clinical interpretation. The cited Ozempic label has no corresponding MASH indication, so that field reads Not listed in the cited label.

Keep indication language brand-specific

Indication sections answer a narrow question: what use and population does this FDA label list for the named product? They help audit marketing language, organize plan questions, and prevent an ingredient from being described as though every brand carries the same FDA uses. The Ozempic and Wegovy statements differ in population and purpose, so a responsible summary preserves those differences without converting them into a choice or ranking.

The scope intentionally excludes comparisons of clinical study results, administration instructions, and personal circumstances. It also gives no conclusion about any reader. Even apparently neutral shorthand can exceed the source: diabetes product, weight product, and heart product each omit qualifying text. Use the complete indication summary above, or quote the current prescribing information directly in an evidence record, rather than relying on a slogan or search-result fragment.

The cited Ozempic label describes a clear, colorless injection in three prefilled, disposable, single-patient-use pen configurations. One configuration contains 2 mg/3 mL and delivers 0.25 mg or 0.5 mg per injection. Another contains 4 mg/3 mL and delivers 1 mg. The third contains 8 mg/3 mL and delivers 2 mg. These specifications identify package configurations; they are not a schedule or user instruction.

For transaction matching, capture total strength, total volume, delivered strength, pen count, and box count exactly as shown on the quote or package. Single-patient-use describes who the pen is assigned to; it should not be shortened to single-dose. If a pharmacy record merely says Ozempic pen, the exact configuration is Not stated. Obtain the product-specific detail before aligning the quote with a commercial offer that is limited by strength or fill definition.

Why the pen presentation belongs in the comparison

The Wegovy label cited here describes prefilled single-dose pens in five presentations: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. The words single-dose distinguish this presentation identity from Ozempic's cited single-patient-use, multi-use pen configurations. That package distinction remains relevant even though both products are injections and both labels name semaglutide.

Create a distinct Wegovy identity key with brand, injection, single-dose pen, strength, volume, number of pens, supply period represented, and transaction channel. Do not copy Ozempic's pen volume, count, or fill definition into that row. The assigned Wegovy label supports the presentation fields, while the cited source set supports no current Wegovy commercial amount. Product identity can therefore be complete even while price remains Not stated.

A durable key for either product includes brand, active ingredient, cited label revision, dosage form, pen type, labeled strength, volume, package count, dispensing pharmacy, and purchase or insurance channel. Add the package's National Drug Code when the actual package or claim supplies it. A blank code stays Not stated until an documented transaction record fills it.

Use the key to reconcile the manufacturer page, plan formulary response, pharmacy quote, checkout summary, and receipt. If one record names only semaglutide, ask which branded product and package it concerns. If two records use different strengths or fill definitions, keep separate rows. Identity matching is more important than forcing a side-by-side number because a mathematically tidy comparison of unlike packages is commercially misleading.

What the dated Ozempic terms cover

The official Ozempic page checked 2026-07-23 displayed commercially covered, uninsured, and self-pay paths separately. For commercially insured people with Ozempic coverage, it said eligible users could pay as little as $25, subject to maximum savings of $100 per month. The page stated eligibility and restrictions, excluded government beneficiaries, defined one injection month as one box containing one Ozempic pen, and reserved program modification or cancellation rights.

That is not a universal $25 price. The floor depends on commercial insurance coverage, program eligibility, correct transaction processing, the monthly maximum, and current terms. The page described the offer as available for up to a three-month prescription and elsewhere stated up to 48 months. Retain both the per-month cap and duration language when recording it. A pharmacy's final processed amount, not the headline alone, completes the dated transaction record.

For uninsured and self-pay injection transactions, the checked page listed a limited new-patient amount of $199 per month for the first two monthly fills at 0.25 mg or 0.5 mg through 2026-12-31. It then listed $349 per month for 0.25 mg, 0.5 mg, or 1 mg and $499 per month for 2 mg. Eligibility and restrictions apply, government beneficiaries are excluded, and Novo Nordisk may modify or cancel the program.

Keep introductory and standard figures in different checklist rows. Label the $199 entry with new-patient status, first two fills, qualifying strengths, one-box fill definition, deadline, self-pay channel, and check date. Label $349 and $499 by strength and standard self-pay status. These are manufacturer-program terms, not list price, plan coverage, or a guaranteed pharmacy amount. Any separate service or fulfillment charge remains Not stated unless a cited source itemizes it.

Keep the Wegovy price marked as unknown here

The cited sources for this check consist of the Ozempic FDA label, the Wegovy FDA label, and the official Ozempic cost page. No cited source states a current Wegovy list price, cash amount, self-pay figure, commercial-savings term, or plan-coverage statistic. Publishing a remembered Wegovy number would break the evidence boundary. The Wegovy commercial fields therefore read Not stated, and no cheapest-product conclusion is available from these sources.

A later refresh needs a current first-party Wegovy source with the exact product form, strength, package, fill definition, channel, insurance category, eligibility, cap, duration, deadline, change rights, and check date. Until then, don't compare Ozempic's $25 floor or $199 introductory amount with an unlabeled Wegovy value from a snippet or coupon site. Missing evidence means the comparison is incomplete; it doesn't mean Wegovy lacks an offer or coverage.

The official Ozempic cost page says coverage depends on the individual plan's formulary and applicable prior-authorization or step-therapy requirements and should be confirmed with the insurer. Ask about the exact Ozempic injection configuration, the plan year, pharmacy network, deductible position, cost-sharing rule, administrative criteria, and response effective date. A manufacturer savings card is not the same record as the plan's coverage determination.

Use the same brand-specific method for Wegovy, but don't imply a plan result from Ozempic's page or from the shared ingredient. Request the formulary record and current plan response for Wegovy itself. Record covered, noncovered, criteria apply, or Not stated only when the source supports that entry. Save the inquiry date and reference number if provided. Coverage can change independently from FDA labeling and independently between products that contain semaglutide.

Ask the plan and pharmacy product-specific questions

Use separate Ozempic and Wegovy columns with rows for active ingredient, indication statements, label revision, injection form, pen type, strength, volume, package count, pharmacy, plan, channel, list price, cash quote, insured amount, savings cap, self-pay amount, introductory and standard periods, deadline, and source date. Enter Not stated whenever documented evidence doesn't answer a row.

Add a document column showing whether the value came from the FDA label, manufacturer terms, insurer response, pharmacy quote, checkout, or receipt. FDA labels control the identity and indication statements used here; they don't establish the household price. Commercial pages supply conditional offer terms; they don't replace a plan response. This source separation makes updates easier because a changed offer can be refreshed without rewriting the FDA identity record.

One error is calling both products semaglutide pens and dropping whether the device is Ozempic single-patient-use or Wegovy single-dose. Another is assigning Wegovy's weight-reduction label to Ozempic, or Ozempic's type 2 diabetes indications to Wegovy. A third is comparing Ozempic's introductory self-pay amount with another product's list price. Each mistake joins fields that the sources keep separate and creates a claim the frozen evidence doesn't support.

Other errors include omitting a program cap, calling a savings floor insurance coverage, using an offer after its deadline, treating one processed fill as a permanent amount, or filling Wegovy's missing price with stale third-party content. Keep every dollar tied to brand, strength, fill, channel, insurance category, term, and date. If those fields can't be aligned, report an incomplete comparison instead of a price winner.

Build the comparison without collapsing categories

The evidence map uses two FDA labels for brand-specific indication and presentation statements and one first-party Ozempic page for dated commercial terms. No cited source supports current Wegovy pricing, so the guide preserves that absence.

Recheck current labels, current manufacturer terms, the exact plan, and the pharmacy quote.